Eledon Pharmaceuticals, Inc.

Equities

ELDN

US28617K1016

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-14 EDT			5-day change	1st Jan Change
3.03 ^USD	+3.06%		+8.99%	+68.33%

06-03	Eledon Pharmaceuticals, Inc. Presents Updated Data from Ongoing Phase 1B Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation	CI
05-13	Eledon Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Eledon Pharmaceuticals, Inc. announced that it has received $49.99901 million in funding

May 08, 2024

On May 9, 2024, Eledon Pharmaceuticals, Inc closed the transaction. The company has received $49,999,010 from 24 investors pursuant to exemption provided under Regulation D. The company has paid fees $1,617,174 to placements.

Latest news about Eledon Pharmaceuticals, Inc.

Eledon Pharmaceuticals, Inc. Presents Updated Data from Ongoing Phase 1B Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation	06-03	CI
Eledon Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-13	CI
Eledon Pharmaceuticals, Inc. announced that it has received $49.99901 million in funding	05-08	CI
Eledon Pharmaceuticals, Inc. Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection	05-07	CI
Eledon Pharmaceuticals, Inc. announced that it expects to receive $49.99901 million in funding	05-05	CI
Eledon Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
Eledon Pharmaceuticals Says 12th Participant Enrolled in Tegoprubart Trial; Shares Rise After Hours	03-25	MT
Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection	03-25	CI
Sector Update: Health Care Stocks Higher in Late Afternoon Trading	03-21	MT
Sector Update: Health Care	03-21	MT
Eledon Pharmaceuticals Says Tegoprubart Used in Kidney Transplant From Pig to Human	03-21	MT
Eledon Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Transcript : Eledon Pharmaceuticals, Inc. - Special Call	11-02
Eledon Pharmaceuticals, Inc. Reports Updated Data from Ongoing Phase 1B Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation	11-02	CI
Eledon Pharmaceuticals Names Eliezer Katz Chief Medical Officer	23-10-23	MT
Eledon Pharmaceuticals, Inc. Appoints of Eliezer Katz as Chief Medical Officer	23-10-23	CI
Eledon Pharmaceuticals Appoints Allan Douglas Kirk to Board of Directors	23-10-02	CI
Noble Capital Initiates Coverage on Eledon Pharmaceuticals with Outperform Rating, $10 Price Target	23-09-27	MT
Eledon's Investigational Antibody Used in Treatment Regimen After Pig-to-Human Heart Transplant	23-09-25	MT
Eledon Pharmaceuticals, Inc. Appoints James Robinson to Its Board of Directors, Effective October 1, 2023	23-09-12	CI
Eledon Pharmaceuticals, Inc. Announces Publication of Study Evaluating Tegoprubart as an Immunomodulatory Monotherapy in Nonhuman Primate Kidney and Islet Allotransplants	23-09-06	CI
Eledon Pharmaceuticals, Inc. Announces First Participant Dosed in Phase 2 Bestow Trial Evaluating Tegoprubart for the Prevention of Rejection in Kidney Transplantation	23-09-05	CI
Eledon Pharmaceuticals, Inc. Announces Dosing of 10th Patient in Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney Transplantation	23-08-16	CI
Eledon Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Eledon Pharmaceuticals, Inc.(NasdaqCM:ELDN) dropped from Russell 3000E Index	23-06-23	CI

Chart Eledon Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Companyâs lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target within the costimulatory CD40/CD40L cellular pathway. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. Tegoprubart is engineered to potentially both improve safety and provides pharmacokinetic, pharmacodynamic, and dosing advantages. CD40L is primarily expressed on activated CD4+ T cells, platelets, and endothelial cells while the CD40 receptor is constitutively expressed on antigen-presenting cells, such as macrophages and dendritic cells, as well as B cells.

Sector

Biotechnology & Medical Research

Calendar

2024-08-07 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.03 USD

Average target price

14 USD

Spread / Average Target

+362.05%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ELEDON PHARMACEUTICALS, INC.	+68.33%	117M
VERTEX PHARMACEUTICALS INCORPORATED	+18.15%	124B
REGENERON PHARMACEUTICALS, INC.	+18.02%	112B
ARGENX SE	+5.07%	22.94B
BIONTECH SE	-12.75%	22.22B
BEIGENE, LTD.	-9.86%	17.02B
GENMAB A/S	-14.97%	16.88B
WUXI APPTEC CO., LTD.	-39.94%	16.87B
NEUROCRINE BIOSCIENCES, INC.	+2.80%	13.63B
SAREPTA THERAPEUTICS, INC.	+27.39%	11.61B

Bio Therapeutic Drugs